MedTrace Logo

Metabolic Effects of Paricalcitol

NCT01003275 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2014-04-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if treatment with paricalcitol, an active form of vitamin D, has beneficial effects on metabolic abnormalities in people with stage 3-4 Chronic Kidney Disease (CKD).

Conditions

Interventions

DRUG

Paricalcitol

Two 1 mcg soft gels by mouth daily for 8 weeks

DRUG

Placebo

Two soft gels by mouth daily for 8 weeks

Sponsors & Collaborators

Principal Investigators

  • Ian H de Boer, MD, MS · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01003275 on ClinicalTrials.gov